FY2026 Earnings Estimate for UTHR Issued By HC Wainwright

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for shares of United Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $27.39 per share for the year, up from their previous estimate of $25.23. HC Wainwright has a “Buy” rating and a $660.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $7.12 EPS, FY2027 earnings at $39.79 EPS, FY2028 earnings at $39.83 EPS, FY2029 earnings at $41.54 EPS and FY2030 earnings at $47.58 EPS.

A number of other analysts have also recently commented on UTHR. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Finally, Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Stock Down 1.0%

Shares of UTHR stock opened at $564.81 on Friday. The business’s fifty day moving average is $504.78 and its 200 day moving average is $477.55. The stock has a market cap of $24.76 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.66 and a beta of 0.75. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the prior year, the company earned $6.19 EPS. The business’s revenue was up 7.4% compared to the same quarter last year.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 361,820 shares of company stock valued at $182,730,910. 10.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new position in United Therapeutics in the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics during the 4th quarter valued at about $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) met its primary endpoint — a material clinical win that supports revenue upside and a larger market opportunity for United Therapeutics. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: HC Wainwright raised its price target to $660, boosted several multi‑year EPS forecasts (FY2026‑FY2029) and lifted some quarterly estimates — keeping a Buy rating, which supports a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Positive Sentiment: Other sell‑side shops have increased targets or reiterated favorable views (Wells Fargo, RBC, Cantor Fitzgerald, Oppenheimer), adding to momentum and analyst coverage breadth. Bank of America Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is elevated, indicating traders are positioning around the Tyvaso news and upcoming earnings — this can amplify intraday moves but is not a fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Valuation and coverage pieces are appearing that model Tyvaso’s contribution; these shape expectations but differ across firms, so watch how consensus revenue/earnings models evolve. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond disclosed multi‑million dollar sales in late March/early April (executed under Rule 10b5‑1 plans). Large, contemporaneous insider sales can create near‑term selling pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.